ホーム › 非小細胞肺癌 › ニューヨーク › Syracuse
Syracuse、NYにおける非小細胞肺癌の臨床試験
Syracuseとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
被験者募集中第3相
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 4マイル先
- Hematology Oncology Associates of CNY at Camillus, Camillus · 8マイル先
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- State University of New York Upstate Medical University, Syracuse
- SUNY Upstate Medical Center-Community Campus, Syracuse
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse · 4マイル先
- 他1件
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
被験者募集中第2相
- State University of New York Upstate Medical University, Syracuse
- Upstate Cancer Center at Hill Radiation Oncology, Syracuse
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
被験者募集中第3相
- SUNY Upstate Cancer Center ( Site 0140), Syracuse
- Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse · 4マイル先
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #76, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, East Syracuse · 4マイル先
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Hematology-Oncology Associates of CNY, East Syracuse · 4マイル先
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
被験者募集中第3相
- SUNY Upstate Medical University, Syracuse
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, East Syracuse · 4マイル先
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Syracuse
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- SUNY Upstate Medical University, Syracuse
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, East Syracuse · 4マイル先
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- State University of New York Upstate Medical University, Syracuse
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
被験者募集中第3相
- SUNY - Upsate Medical Centre, Syracuse
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Hematology Oncology Associates of Central New York, East Syracuse · 4マイル先
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Syracuseにおける他の研究
- がん（全種類）9件の研究
- 前立腺がん9件の研究
- 非筋層浸潤性膀胱癌8件の研究
- 卵巣がん7件の研究
- 子宮内膜がん7件の研究
- 肥満症6件の研究
- 肺がん6件の研究
- 大腸癌5件の研究
- 黄斑変性症5件の研究
- 急性骨髄性白血病5件の研究
- 2型糖尿病5件の研究
- ループス5件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。